GSK plc (LON:GSK) drops after cough medicine blow wipes £2.4 billion off market value
GSK plc shed roughly £2.36 billion in market value on Friday after mixed phase III data halted the camlipixant chronic-cough programme. The decline surpassed GSK's 2023 acquisition cost for BELLUS by approximately £765 million.